CHICAGO (Reuters) – Final data from Gilead Sciences Inc’s antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo, one day faster than previously reported preliminary data showed, the company and researchers said on Thursday.
(Reporting by Julie Steenhuysen; Editing by Chris Reese)
